Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Moderate Buy” by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $18.00.

Several research analysts recently weighed in on EPRX shares. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Stifel Nicolaus initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a “buy” rating and a $25.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Finally, Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EPRX. Persistent Asset Partners Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter valued at about $25,000. BlackRock Inc. bought a new stake in Eupraxia Pharmaceuticals during the 2nd quarter worth approximately $40,000. Aptus Capital Advisors LLC bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $76,000. Guardian Wealth Advisors LLC NC acquired a new stake in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $76,000. Finally, Bank of America Corp DE raised its holdings in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the period.

Eupraxia Pharmaceuticals Price Performance

Shares of EPRX opened at $6.77 on Monday. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals has a 1 year low of $5.04 and a 1 year high of $9.32. The stock has a market cap of $440.19 million, a P/E ratio of -6.45 and a beta of 1.08. The stock’s 50-day moving average price is $6.41 and its two-hundred day moving average price is $7.21.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, equities analysts predict that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.